<DOC>
	<DOCNO>NCT01458080</DOCNO>
	<brief_summary>Hepatitis C Virus ( HCV ) lead cause chronic liver disease ( CLD ) worldwide . Current mainstay treatment combination therapy pegylated interferon ribavarin . Thrombocytopenia treatment related adverse event complication chronic liver disease often necessitate dose reduction discontinuation patient . Revolade®/Promacta® ( eltrombopag ) oral second generation thrombopoietic growth factor development treatment thrombocytopenia associate various condition , include secondary thrombocytopenia relate CLD hepatitis C. In 2009 phase III trial CLD patient undergo elective invasive procedure ( ELEVATE ) terminate early due imbalance thromboembolic event ( TEE ) placebo eltrombopag arm . Currently , two global interventional Phase III trial ( ENABLE 1 ENABLE 2 ) conduct approximately 1500 patient evaluate efficacy eltrombopag enable HCV patient achieve sustain viral response . Due similarity patient group ELEVATE ENABLE , concern invasive procedure may influence risk TEE ENABLE population . This observational , non-interventional , retrospective , multicentre , nest case-control study collect data chart abstraction medical record review augment data ENABLE case report form particularly regard invasive procedure . The study population include case control draw ~1500 participant ENABLE trial . All eligible case TEE include study case . All patient participate ENABLE trial experience TEE , eligible select control . Case report form develop enable standardize data capture . The Sponsor contract Clinical Research Organization , Outcome Sciences Inc manage study . ENABLE investigator work Outcome staff obtain relevant information treat physician ( e.g . surgeon ) facility invasive procedure perform ( pre-operative test , peri-operative course , diagnostic test TEE ) . Single point abstraction perform obtain data medical record additional data resource obtain investigator ( e.g. , operative note , anesthesia record ) . Analyses conduct use logistic regression model estimate risk . The primary objective study evaluate increase risk TEE among patient invasive procedure expose eltrombopag ( ENABLE trial ) .</brief_summary>
	<brief_title>WEUSKOP5410 : Observational Study ENABLE Clinical Trials</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<criteria>The inclusion criterion casecontrol study patient participate openlabel phase randomization phase ENABLE 1 ENABLE 2 clinical trial . Inclusion criterion ENABLE clinical trial include age &gt; 18 year evidence chronic HCV infection candidate peginterferon ribavirin combination antiviral therapy baseline platelet count &lt; 75,000/µl significant anemia neutropenia . Exclusion criterion ENABLE clinical trial include : nonresponders previous treatment peginterferon ribavirin unless due thrombocytopenia decompensated liver disease , e.g . ChildPugh score &gt; 6 history ascites hepatic encephalopathy current evidence ascites serious cardiac , cerebrovascular , pulmonary disease document history clinically significant bleed oesophageal gastric varix , haemoglobinopathy , e.g . sickle cell anemia , thalassemia major , history arterial venous thrombosis , hepatocellular carcinoma , Human Immunodeficiency Virus ( HIV ) Hepatitis B infection disease condition associate active bleeding require anticoagulation history malignancy , history alcohol/drug abuse dependence within 6 month study start history platelet clump prevents reliable measurement platelet count history major organ transplantation exist functional graft evidence portal vein thrombosis abdominal imaging within 3 month baseline visit . No additional exclusion criterion apply casecontrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>ENABLE</keyword>
	<keyword>invasive procedure</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Thromboembolic event</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
</DOC>